Inventor · disambiguated record
Gavin Macbeath
Also filed as: MACBEATH GAVIN
9 granted patents·25 pending applications·71 citations·filing 2000–2023
85Inventor score
Files withTSCAN THERAPEUTICS INC9HARVARD COLLEGE8MERRIMACK PHARMACEUTICALS INC6GARCIA GABRIELA2UNIV CALIFORNIA2
Top patents by PatentIndex Score
34 records- 0184US9688761B2Biomarker profiles for predicting outcomes of cancer therapy with ERBB3 inhibitors and/or chemotherapiesMERRIMACK PHARMACEUTICALS INC·Filed 2015·Granted Jun 27, 2017·4 cites·24 claims
- 0284US7323346B2Screening for gestational disordersGEN HOSPITAL CORP·Filed 2004·Granted Jan 29, 2008·24 cites·26 claims
- 0383US6824987B1Small molecule printingHARVARD COLLEGE·Filed 2000·Granted Nov 30, 2004·19 cites·9 claims
- 0480US7063979B2Interface between substrates having microarrays and microtiter platesHARVARD COLLEGE·Filed 2002·Granted Jun 20, 2006·23 cites·59 claims
- 0574US10273304B2Biomarker profiles for predicting outcomes of cancer therapy with ERBB3 inhibitors and/or chemotherapiesMERRIMACK PHARMACEUTICALS INC·Filed 2017·Granted Apr 30, 2019·1 cites·36 claims
- 0664US2025249039A1Prame immunogenic peptides, binding proteins recognizing prame immunogenic peptides, and uses thereofTSCAN THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 0764US2025288675A1Multiplexed t cell receptor compositions, combination therapies, and uses thereofTSCAN THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 0863US2005095639A1Small molecule printingFiled 2004·Application pending·0 cites
- 0958US2024190931A1Magec2 immunogenic peptides, binding proteins recognizing magec2 immunogenic peptides, and uses thereofTSCAN THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1058US2023272049A1Binding proteins recognizing hpv16 e7 antigen and uses thereofTSCAN THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1157US2013123134A1Small molecule printingHARVARD COLLEGE·Filed 2012·Application pending·0 cites
- 1256US2006115808A1Microarrays of functional biomolecules, and uses thereforUNIV CALIFORNIA·Filed 2005·Application pending·0 cites
- 1355US10159952B2Method for lysing a single cell in a solid tissueHARVARD COLLEGE·Filed 2017·Granted Dec 25, 2018·0 cites·16 claims
- 1455US2017210810A1Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapiesMERRIMACK PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 1553US2024197877A1Binding proteins recognizing ha-2 antigen and uses thereofTSCAN THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1652US9260519B2Frizzled 2 as a target for therapeutic antibodies in the treatment of cancerGUJRAL TARANJIT S·Filed 2012·Granted Feb 16, 2016·0 cites·24 claims
- 1752US2006115810A1Microarrays of functional biomolecules, and uses thereforHARVARD COLLEGE·Filed 2005·Application pending·0 cites
- 1852US2023241205A1Sars-cov-2 immunodominant peptides and uses thereofTSCAN THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1952US2006115809A1Microarrays of functional biomolecules, and uses thereforUNIV CALIFORNIA·Filed 2005·Application pending·0 cites
- 2052US2023398205A1Sars-cov-2 immunodominant peptide constructs and uses thereofTSCAN THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2152US2023398217A1Binding proteins recognizing ha-1 antigen and uses thereofTSCAN THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2250US9765401B2Frizzled 2 as a target for therapeutic antibodies in the treatment of cancerHARVARD COLLEGE·Filed 2016·Granted Sep 19, 2017·0 cites·25 claims
- 2349US2018002754A1Frizzled 2 as a target for therapeutic antibodies in the treatment of cancerHARVARD COLLEGE·Filed 2017·Application pending·0 cites
- 2447US2015246335A1Methods for multiplex analytical measurements in single cells of solid tissuesHARVARD COLLEGE·Filed 2013·Application pending·0 cites
- 2546US2023287390A1Compositions and methods for identifying epitopesTSCAN THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2643US2002076727A1Microarrays of functional biomolecules and uses thereforFiled 2001·Application pending·0 cites
- 2741US2014248280A1Anti-erbb3 antibodies in combination with paclitaxel for treatment of gynecological cancersKUBASEK WILLIAM·Filed 2012·Application pending·0 cites
- 2840US10184006B2Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitorsMERRIMACK PHARMACEUTICALS INC·Filed 2016·Granted Jan 22, 2019·0 cites·18 claims
- 2938US2004038428A1Protein microarraysFiled 2003·Application pending·0 cites
- 3038US2015231238A1Overcoming resistance to erbb pathway inhibitorsGARCIA GABRIELA·Filed 2012·Application pending·0 cites
- 3137US2002102617A1Protein microarraysFiled 2001·Application pending·0 cites
- 3233US2017306415A1Predicting tumor responses to antibodies against hepatocyte growth factor (hgf) and/or its cognate receptor, c-metMERRIMACK PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 3332US2014134170A1Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancersGARCIA GABRIELA·Filed 2012·Application pending·0 cites
- 3431US2016303232A1Combination treatments with seribantumabMERRIMACK PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Gavin Macbeath files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →